Literature DB >> 8550824

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

D A D'Alessio1, R Vogel, R Prigeon, E Laschansky, D Koerker, J Eng, J W Ensinck.   

Abstract

Glucagon-like peptide 1 (GLP-1) is an insulinotropic hormone released after nutrient ingestion which is known to augment insulin secretion, inhibit glucagon release, and promote insulin-independent glucose disposition. To determine the overall effect of GLP-1 on glucose disposition after a meal we studied a group of healthy, conscious baboons before and after intragastric glucose administration during infusions of saline, and two treatments to eliminate the action of GLP-1: (a) exendin-[9-39] (Ex-9), a peptide receptor antagonist of GLP-1; or (b) an anti-GLP-1 mAb. Fasting concentrations of glucose were higher during infusion of Ex-9 than during saline (4.44 +/- 0.05 vs. 4.16 +/- 0.05 mM, P < 0.01), coincident with an elevation in the levels of circulating glucagon (96 +/- 10 vs. 59 +/- 3 ng/liter, P < 0.02). The postprandial glycemic excursions during administration of Ex-9 and mAb were greater than during the control studies (Ex-9 13.7 +/- 2.0 vs. saline 10.0 +/- 0.8 mM, P = 0.07; and mAb 13.6 +/- 1.2 vs. saline 10.6 +/- 0.9 mM, P = 0.044). The increments in insulin levels throughout the absorption of the glucose meal were not different for the experimental and control conditions, but the insulin response in the first 30 min after the glucose meal was diminished significantly during treatment with Ex-9 (Ex-9 761 +/- 139 vs. saline 1,089 +/- 166 pM, P = 0.044) and was delayed in three of the four animals given the neutralizing antibody (mAb 946 +/- 262 vs. saline 1,146 +/- 340 pM). Thus, elimination of the action of GLP-1 impaired the disposition of an intragastric glucose meal and this was at least partly attributable to diminished early insulin release. In addition to these postprandial effects, the concurrent elevation in fasting glucose and glucagon during GLP-1 antagonism suggests that GLP-1 may have a tonic inhibitory effect on glucagon output. These findings demonstrate the important role of GLP-1 in the assimilation of glucose absorbed from the gut.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550824      PMCID: PMC507071          DOI: 10.1172/JCI118380

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Studies of a simplified plasma insulin immunoassaay using cellulose powder.

Authors:  D S Zaharko; L V Beck
Journal:  Diabetes       Date:  1968-07       Impact factor: 9.461

2.  Intestinal factors in the control of insulin secretion.

Authors:  N McIntyre; C D Holdsworth; D S Turner
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

3.  Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle.

Authors:  M L Villanueva-Peñacarrillo; A I Alcántara; F Clemente; E Delgado; I Valverde
Journal:  Diabetologia       Date:  1994-11       Impact factor: 10.122

4.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

Authors:  R N Bergman; L S Phillips; C Cobelli
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

5.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus.

Authors:  H S Seltzer; E W Allen; A L Herron; M T Brennan
Journal:  J Clin Invest       Date:  1967-03       Impact factor: 14.808

6.  Early and late insulin response as predictors of NIDDM in Pima Indians with impaired glucose tolerance.

Authors:  D K Nagi; W C Knowler; M A Charles; Q Z Liu; R L Hanson; D R McCance; D J Pettitt; P H Bennett
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

7.  Glucagon-like peptide-1 is a physiological incretin in rat.

Authors:  Z Wang; R M Wang; A A Owji; D M Smith; M A Ghatei; S R Bloom
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

8.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.

Authors:  M J Perley; D M Kipnis
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

9.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Authors:  C F Deacon; A H Johnsen; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

10.  Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus.

Authors:  A Vaag; J E Henriksen; S Madsbad; N Holm; H Beck-Nielsen
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  27 in total

Review 1.  The role of gut hormones in glucose homeostasis.

Authors:  Daniel J Drucker
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  New ways in which GLP-1 can regulate glucose homeostasis.

Authors:  David A D'Alessio; Darleen A Sandoval; Randy J Seeley
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Authors:  Jixin Zhong; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Clin Lipidol       Date:  2015

Review 4.  The incretin system and cardiometabolic disease.

Authors:  Paul E Szmitko; Lawrence A Leiter; Subodh Verma
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

5.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

6.  β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.

Authors:  Benedikt A Aulinger; Torsten P Vahl; Hilary E Wilson-Pérez; Ron L Prigeon; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2015-03-31       Impact factor: 5.958

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.

Authors:  Marzieh Salehi; Torsten P Vahl; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2008-09-30       Impact factor: 5.958

9.  Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

Authors:  Marzieh Salehi; Benedict Aulinger; Ronald L Prigeon; David A D'Alessio
Journal:  Diabetes       Date:  2010-03-09       Impact factor: 9.461

10.  The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?

Authors:  Benedikt A Aulinger; Torsten P Vahl; Ron L Prigeon; David A D'Alessio; Deborah A Elder
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-03-15       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.